Activation of EGFR [48] has been shown to contribute to COPD-associated phenotypes such as mucus overproduction and secretion, which would explain why inhibition reduces the MUC5AC levels within the bronchospheres lumen despite CSE treatment. Here, MUC5AC is linked to chronic obstructive pulmonary disease.